Clinical Trial Update: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial [Phase 2]

View source ↗

Summary

Phase II open-label single-arm study evaluating efficacy and safety of anlotinib in advanced or metastatic pheochromocytoma/paraganglioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Nanjing First Hospital, Nanjing Medical University | Conditions: Advanced or Metastatic Paraganglioma/ Pheochromocytoma | Phase 2 | Status: UNKNOWN